On January 14, 2019 Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, reported two upcoming presentations at the 2019 Gastrointestinal Cancer Symposium being held in San Francisco, January 17-19, 2019 (Press release, Five Prime Therapeutics, JAN 14, 2019, View Source [SID1234532642]). Data will be presented from the Phase 1/3 FIGHT Study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer. The study design of the randomized phase 2 study of cabiralixumab in combination with nivolumab and chemotherapy in advanced pancreatic ductal adenocarcinoma will also be presented. Here are the details of the two poster presentations:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: Phase 1 Results from the Phase 1/3 FIGHT Study Evaluating bemarituzumab and mFOLFOX6 in Advanced Gastric/GEJ Cancer
Abstract Number: Board J1, Abstract #91
Poster Session: A – Cancer of the Esophagus and Stomach
Date & Time: Thursday, January 17, 19, 11:30-1pm and 5:30-6:30pm
Title: A Randomized Phase 2 Study of cabiralizumab (cabira) + nivolumab (nivo) ± chemotherapy (chemo) in Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Abstract Number: Board Q4 Abstract #TPS465
Poster Session: B – Pancreatic, Small Bowel, Hepatobiliary
Date & Time: Friday, January 18, 2019, 11:30-1pm and 5:30-6:30pm
The poster abstracts will be available on January 14, 2019 at 5:00 PM EST at the ASCO (Free ASCO Whitepaper) Meeting Library and the posters can be found on Five Prime Therapeutics’ Scientific Publications page after presentation at the conference.
About Bemarituzumab (FPA008)
Bemarituzumab is a first-in-class, isoform-selective, humanized monoclonal antibody in clinical development as a targeted immunotherapy for tumors that overexpress FGFR2b, a splice variant of a receptor for some members of the fibroblast growth factor (FGF) family. Bemarituzumab has been engineered for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) to increase direct tumor cell killing by recruiting natural killer (NK) cells. Clinical results to date suggest that the specificity of bemarituzumab avoids the dose-limiting toxicities that have been seen with less selective pan-FGFR tyrosine kinase inhibitors that act on multiple FGFRs, including FGFR2.
In December 2017, Five Prime and Zai Lab announced a collaboration for the development and commercialization of bemarituzumab in Greater China. Zai Lab will manage the Phase 3 portion of the FIGHT trial in China.
About Cabiralizumab (FPA008)
Cabiralizumab is an investigational antibody that inhibits the CSF-1 receptor and has been shown in preclinical models to block the activation and survival of monocytes and macrophages. Inhibition of CSF1R in preclinical models of several cancers reduces the number of immunosuppressive tumor-associated macrophages (TAMs) in the tumor microenvironment, thereby facilitating an immune response against tumors. Cabiralizumab is currently in clinical trials in oncology indications. Cabiralizumab is being developed under an exclusive worldwide license and collaboration agreement entered into with Bristol-Myers Squibb (BMS) in October 2015.